Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ...
SAN FRANCISCO--(BUSINESS WIRE)--In a presentation to investors today at the 29th Annual J. P. Morgan Healthcare Conference, Biogen Idec (NASDAQ: BIIB) Chief Executive Officer George Scangos, Ph.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results